Common Contracts

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. EXCLUSIVE CROSS- LICENSE, TECHNOLOGY TRANSFER, AND REGULATORY MATTERS AGREEMENT

Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement • January 13th, 2015 • Bellerophon Therapeutics LLC • Pharmaceutical preparations • Delaware

• Contract Type
  Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement
• Filed
  January 13th, 2015
• Company
  Bellerophon Therapeutics LLC
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS EXCLUSIVE CROSS-LICENSE, TECHNOLOGY TRANSFER, AND REGULATORY MATTERS AGREEMENT (the “Agreement”), is dated February 9, 2014 (the “Effective Date”) by and between INO Therapeutics LLC, a Delaware limited liability company, d/b/a Ikaria, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 (“Ikaria”), and Bellerophon Pulse Technologies LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 (“Pulse Technologies”). Ikaria and Pulse Technologies may be individually referred to as a “Party” and together as the “Parties.”

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. EXCLUSIVE CROSS- LICENSE, TECHNOLOGY TRANSFER, AND REGULATORY MATTERS AGREEMENT

Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement • May 14th, 2014 • Bellerophon Therapeutics LLC • Pharmaceutical preparations • Delaware

• Contract Type
  Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement
• Filed
  May 14th, 2014
• Company
  Bellerophon Therapeutics LLC
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS EXCLUSIVE CROSS-LICENSE, TECHNOLOGY TRANSFER, AND REGULATORY MATTERS AGREEMENT (the “Agreement”), is dated February 9, 2014 (the “Effective Date”) by and between INO Therapeutics LLC, a Delaware limited liability company, d/b/a Ikaria, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 (“Ikaria”), and Bellerophon Pulse Technologies LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 (“Pulse Technologies”). Ikaria and Pulse Technologies may be individually referred to as a “Party” and together as the “Parties.”